Capecitabine in advanced hepatocellular carcinoma.

@article{Murer2016CapecitabineIA,
  title={Capecitabine in advanced hepatocellular carcinoma.},
  author={Francesca Murer and Caterina Pozzan and Giulia Peserico and Fabio Farinati},
  journal={Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver},
  year={2016},
  volume={48 10},
  pages={
          1260-1
        }
}
Since sorafenib was demonstrated to be active as a systemic reatment in hepatocellular carcinoma (HCC) [1,2], no new drug ith molecular target has shown any efficacy in patients proressing under sorafenib or intolerant to its administration. We herefore read with great interest the report by Granito in DLD 3] on metronomic capecitabine in HCC after sorafenib failure. tandard chemotherapy has never been proved effective in HCC [4], ince HCC cells actively express the MDR proteins [5], and since… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-2 OF 2 CITATIONS

CD13 Inhibition Enhances Cytotoxic Effect of Chemotherapy Agents

  • Front. Pharmacol.
  • 2018
VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS

Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation

Franco Trevisani, Giovanni Brandi, +12 authors Giovan Giuseppe Di Costanzo
  • Journal of Cancer Research and Clinical Oncology
  • 2017
VIEW 2 EXCERPTS
CITES BACKGROUND & METHODS

References

Publications referenced by this paper.
SHOWING 1-5 OF 5 REFERENCES

Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure.

  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2015

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

C Ann-Lii, K Yoon-Koo, C Zhendong
  • Lancet Oncology 2009;10:25–34
  • 2009

Similar Papers

Loading similar papers…